<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3344">
  <stage>Registered</stage>
  <submitdate>4/11/2011</submitdate>
  <approvaldate>4/11/2011</approvaldate>
  <nctid>NCT01467375</nctid>
  <trial_identification>
    <studytitle>Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes</studytitle>
    <scientifictitle>An Open Label, Non Comparative, Multicentre Extension Trial to Assess the Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Who Have Completed BIAsp-1234</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BIASP-1361</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - biphasic insulin aspart

Experimental: A - 


Treatment: drugs: biphasic insulin aspart
Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Occurrence of adverse events</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Frequency of hypoglycaemic episodes</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>HbA1c (glycosylated haemoglobin)</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects must have been correctly included in and completed BIAsp-1234</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Persistent non-compliance with study medication, visit schedules or other trial
             specific procedures during the preceding trial

          -  Fulfilment of any withdrawal criteria prior to and including the final visit of the
             BIAsp-1234.

          -  Females only: breast feeding, intention of becoming pregnant, or judged to be using
             inadequate contraceptive measures (adequate contraceptive methods are
             sterilisation,IUD (Intra Uterine Device), oral contraceptives or barrier methods)

          -  Known or suspected allergy to trial product or related products

          -  Development since entry into the previous trial of late diabetic micro or macro
             vascular complications, which in the opinion of the Investigator indicates a
             progressed state of disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>8/01/2001</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>89</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>22/10/2004</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Novo Nordisk Investigational Site - Broadmeadow</hospital>
    <hospital>Novo Nordisk Investigational Site - Parkville</hospital>
    <hospital>Novo Nordisk Investigational Site - Ashford</hospital>
    <hospital>Novo Nordisk Investigational Site - Auchenflower</hospital>
    <hospital>Novo Nordisk Investigational Site - Launceston</hospital>
    <hospital>Novo Nordisk Investigational Site - Nowra</hospital>
    <hospital>Novo Nordisk Investigational Site - Ringwood</hospital>
    <hospital>Novo Nordisk Investigational Site - Rooty Hill</hospital>
    <postcode>2292 - Broadmeadow</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>5035 - Ashford</postcode>
    <postcode>4066 - Auchenflower</postcode>
    <postcode>7250 - Launceston</postcode>
    <postcode>2540 - Nowra</postcode>
    <postcode>3134 - Ringwood</postcode>
    <postcode>2766 - Rooty Hill</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Hull</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatoon</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted in Oceania and North America. The aim of this trial is to assess the
      long term safety and efficacy of biphasic insulin aspart 30 in subjects with type 2 diabetes
      who have completed the BIAsp-1234 trial.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01467375</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Registry (GCR, 1452)</name>
      <address>Novo Nordisk A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>